KRAS G12-mutant NSCLC

Clinical trials for KRAS G12-mutant NSCLC explained in plain language.

Never miss a new study

Get alerted when new KRAS G12-mutant NSCLC trials appear

Sign up with your email to follow new studies for KRAS G12-mutant NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Terminated 1

New cancer pill shows early promise, but trial halted

Disease control Stopped early

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…

Matched conditions: KRAS G12-MUTANT NSCLC

Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control

Last updated Jul 11, 2026 00:00 UTC

KRAS G12-mutant NSCLC

Get alerted when new KRAS G12-mutant NSCLC trials appear

New cancer pill shows early promise, but trial halted